IMARA is a clinical-stage biopharmaceutical company, focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Co.'s pipeline is built on the therapeutic potential of Co.'s initial product candidate, IMR-687, which is a treatment for sickle cell disease, and ß-thalassemia. IMR-687 is a potent small molecule inhibitor of phosphodiesterase-9, that has a multimodal mechanism of action that acts primarily on red blood cells, and has the potential to act on white blood cells, adhesion mediators and other cell types that are implicated in these disorders. The IMRA stock yearly return is shown above.
The yearly return on the IMRA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|